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Inﬂammation has been proposed to be a crucial component in the pathogenesis of
atherothrombosis [1]. Evidence has accumulated over the past two decades suggesting that
inﬂammation plays a major role in all stages of the atherothrombotic process, including
the sudden rupture of apparently stable plaque [2]. The interaction of lipid accumulation
and immune function appears to both promote premature atherosclerosis and accelerate
plaque ﬁssuring, a process that exposes the underlying matrix to circulating thrombo-
genic factors and ultimately leads to platelet adhesion, vessel occlusion and downstream
hypoxia [3]. Clinical studies [4,5] have also supported a link between chronic inﬂammation
and coronary heart disease (CHD), and inﬂammatory markers have received much atten-
tion as emerging factors that could account for some of the unexplained variability in CHD
risk. C-reactive protein (CRP), an acute phase plasma protein synthesised by the liver, is a
sensitive, non-speciﬁc marker of inﬂammation and has been extensively studied over the
past two decades [1]. Much uncertainty remains, however, about whether circulating levels
of CRP are a causal risk factor for vascular disease or are mainly correlated to conventional
cardiovascular risk factors or markers of subclinical disease, or some combination of these
possibilities.
A literature-based meta-analysis published in 2004 involving 22 prospective studies
reported an odds ratio for CHD, adjusted for several conventional risk factors, of 1.6
(95% conﬁdence interval [CI] 1.5—1.7) in a comparison of people with baseline CRP
concentrations in the top third to those in the bottom third of the population dis-
tribution (corresponding to values of about 2.4mg/L vs 1mg/L) [6]. This odds ratio
was similar in magnitude to those reported for some established causative risk fac-
tors (e.g., low-density lipoprotein cholesterol or systolic blood pressure), as well as to
those for some other non-speciﬁc circulating markers of inﬂammation [7,8]. By con-
trast, an odds ratio of 2.0 (95% CI 1.6—2.5) for CHD was reported in an earlier review
of the 11 initial prospective studies of CRP [9] and even more extreme odds ratios have
been reported in some earlier individual studies. More recently, the Emerging Risk Fac-
tors Collaboration (ERFC) [10] reviewed the associations between CRP concentrations,
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stablished cardiovascular risk factors and vascular risk in a
ollaborative analysis of individual data from 54 prospective
tudies. In contrast with literature-based reviews (which
ave access to only published or limited aggregated data),
his large pooled analysis involving primary data was able
o reliably characterize the magnitude and the shape of any
ose-response relationships (under a range of various cir-
umstances), provide a consistent approach to adjustment
or possible confounding factors, correct for within-person
ariability in concentrations of CRP and of possible con-
ounding factors, and investigate any potential sources of
eterogeneity. In a total of 160,309 individuals without a
istory of CHD or stroke, comprising 27,769 participants
hat experienced a ﬁrst-ever non-fatal or fatal event, CRP
oncentration was associated with a variety of different
onditions, each of which was broadly similar in magni-
ude, including CHD, ischaemic stroke and deaths due to
everal common cancers and other non-vascular causes. Fur-
hermore, the strength of association of CRP concentration
ith ischaemic vascular disease reduced considerably after
djustment for several conventional risk factors and other
arkers of inﬂammation (such as ﬁbrinogen).
Even analyses in the ERFC (as in all observational
nalyses), however, are limited in their ability to judge
ausality [11], particularly as they are susceptible to bias
y reverse association and by confounding. Although such
istortion was minimized, but not eliminated, in the ERFC
y studying initially disease-free individuals and by appropri-
tely adjusting for potential known confounders, statistical
djustment is potentially limited because not all rele-
ant confounders have been (or can be) measured in
bservational studies. In the absence of large-scale ran-
omized controlled trials of suitable interventions, studies
hat employ genetic variants that are associated with spe-
iﬁc changes in circulating CRP concentration can help
o provide an alternative approach to assess the causal
elevance of CRP to disease risk (i.e., ‘‘Mendelian random-
zation’’ analyses) [12]. A number of studies have identiﬁed
everal single-nucleotide polymorphisms (SNPs) within the
RP gene that inﬂuence the circulating concentration of
he protein [13,14], but they are not materially associ-
ted with any established or emerging cardiovascular risk
arkers, suggesting that these SNPs can serve as unbi-
sed proxy for CRP and are useful as tools for use in
endelian randomization analyses. Such studies (includ-
ng a recent meta-analysis involving 28,000 CHD patients
nd 100,000 controls [15]) have reported essentially null
ssociations between CRP-related genotypes and CHD risk
16,17], reducing the likelihood of a major causal role
or CRP in CHD, but even more powerful studies are
eeded to conﬁrm or exclude any modest, but potentially
till important, causative effect of CRP concentration on
HD.
The Justiﬁcation for the Use of Statins in Primary
revention: an Intervention Trial Evaluating Rosuvastatin
JUPITER) trial randomized 17,802 people (62% men, 16%
mokers) with no evidence of cardiovascular disease, ele-
ated (> 2mg/L; median, 4.3mg/L; interquartile range,
.8—7.1mg/L) CRP concentrations and low-density lipopro-
ein concentrations of < 3.4mmol/L (< 130mg/dL) (median,
.8mmol/L [108mg/dL]) to rosuvastatin or placebo [18].
ollowing a 44% relative-risk reduction in the primary
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ndpoint of myocardial infarction, stroke, arterial revascu-
arization, hospitalization for unstable angina or death from
ardiovascular causes, the Independent Data Safety Mon-
toring Board halted the trial earlier than planned. When
he trial was terminated, only 1076 participants had 4 years
f follow-up, and 2705 had 3 years of follow-up (median
ollow-up, 1.9 years; maximum, 5.0 years). Each individual
omponent of the JUPITER primary endpoint was signif-
cantly reduced: 54% reduction in myocardial infarction,
6% reduction in arterial revascularization and 48% reduc-
ion in fatal and non-fatal stroke, with a 51% reduction
n the rate of ischemic stroke and no difference in the
ates of haemorrhagic stroke [19]. But, as statins potently
ffect low-density lipoprotein cholesterol concentrations,
his trial was not able to provide speciﬁc causal infer-
nces about CRP. Separate analyses from the JUPITER trial
ave reported associations between the degree of CRP-
owering achieved and risk of cardiovascular disease [20].
ompared to participants receiving placebo, a 65% reduc-
ion in vascular events was observed in subjects allocated
o rosuvastatin who achieved both low-density lipopro-
ein cholesterol < 1.8mmol/L and CRP < 2mg/L versus a 33%
eduction in those who achieved one or neither target. A 79%
eduction in vascular events was also found in subjects who
chieved a low-density lipoprotein cholesterol concentra-
ion < 1.8mmol/L and CRP < 1mg/L [20]. As acknowledged in
his report, however, these analyses may have been liable
o bias because they have not been based on the trials’ ran-
omized treatment allocations. Although this trial cannot
irectly address whether lowering inﬂammation alone low-
rs vascular risk, the JUPITER ﬁndings are important because
hey extend the evidence-base for statins to individuals who
re at lower risk than those targeted by current cardiovascu-
ar risk thresholds and because they conﬁrm that low-density
ipoprotein cholesterol lowering is effective in cardiovascu-
ar prevention, even at low starting low-density lipoprotein
holesterol concentrations.
In aggregate, therefore, the available evidence does not
urrently support CRP itself as a direct causal mediator
n the development of CHD, but its role in vascular dis-
ase is not fully resolved, and it remains unknown whether
nhibiting inﬂammation in general will decrease the rate
f vascular events. Further research is also required to
ddress other clinically relevant questions concerning CRP,
uch as evaluation of the incremental value of CRP measure-
ent beyond established risk factors for cardiovascular risk
ssessment [21]. Several individual prospective studies have
eported on the potential utility of CRP measurements for
ardiovascular disease risk prediction and a recent analy-
is tried to assess the predictive performance of CRP in two
rospective cohort studies supplemented by a systematic
eview of relevant data from 31 published prospective stud-
es [22]. This review suggested that although elevated CRP
oncentrations were associated consistently with increased
HD risk, measurement of CRP concentrations provides little
mprovement in CHD risk prediction when assessed using sev-
ral metrics of predictive value [22]. Relevant investigations
n the ERFC should, however, provide a more reliable and
obust assessment about whether measurement of circulat-
ng CRP concentration can help to better identify individuals
t increased risk of CHD than measurement of conventional
isk factors alone.
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